<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204564</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT04204564</nct_id>
  </id_info>
  <brief_title>VISION and VQI Paclitaxel Safety Analysis</brief_title>
  <acronym>VISION-VQI</acronym>
  <official_title>Vascular Implant Surveillance and Interventional Outcomes Network and the Vascular Quality Initiative Paclitaxel Safety Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Medical Device Epidemiology Network (MDEpiNet)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society for Vascular Surgery Patient Safety Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives

        1. The VQI-VISION Paclitaxel Device Safety Analysis seeks to assess the comparative safety
           of paclitaxel-coated balloons and stents in the treatment of PAD through analysis of the
           Vascular Quality Initiative (VQI) Peripheral Vascular Intervention (PVI) registry module
           with linkage to claims. By linking VQI patients to Medicare claims retrospectively from
           2012 to 2016, we will be able to identify additional paclitaxel devices enabling
           longitudinal follow-up of mortality out to 5 years for paclitaxel-eluting stents and 3
           years for paclitaxel-coated balloons.

        2. To analyze factors associated with mortality, specifically comparing paclitaxel patients
           surviving vs. paclitaxel patients with mortality. The goal is to identify independent
           factors predictive of mortality in US pivotal trials and model registry data exposures
           with sufficient factors to track competing risk paradox and show emulation or not of
           mortality outcomes with both PTX and PTA exposures.

        3. To confirm the effectiveness of paclitaxel devices by comparing reintervention for
           paclitaxel and non-paclitaxel devices. In-hospital mortality from open and percutaneous
           target vessel revascularization (TVR) will be reported to determine the impact of
           subsequent revascularizations on survival. Major amputation will be comparted for
           patients with chronic limb-threatening ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed safety analyses will evaluate two types of paclitaxel-coated interventional
      devices used to treat PAD and compare patient outcomes with propensity score-matched patients
      of similar risk who receive non-paclitaxel devices.

      The primary outcome will be freedom from all-cause death using propensity-matched survival
      analysis.

      Three principle analyses are planned:

        1. Paclitaxel DCB (including the Bard Lutonix, Medtronic In.Pact Admiral, and Philips
           Spectranetics Stellarex DCB's) as compared with propensity-matched patients treated with
           plain balloons.

        2. Paclitaxel delivering DES (Cook Zilver PTX) as compared with propensity-matched cases
           using bare-metal stents (BMS).

        3. Patients treated with either Paclitaxel DCB or Paclitaxel DES compared with
           propensity-matched controls (with DCB patients matched to patients treated with plain
           balloons, and DES patients matched to patients treated with BMS).

      Note that this analysis is planned at the device class level and is not intended to compare
      early or late mortality between specific devices or brands.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2012</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>overall mortality</measure>
    <time_frame>1 year</time_frame>
    <description>death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall mortality</measure>
    <time_frame>3 years</time_frame>
    <description>death from any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall mortality</measure>
    <time_frame>5 years</time_frame>
    <description>death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularization (TVR)</measure>
    <time_frame>1-3-5 years</time_frame>
    <description>repeat intervention on the SFA-popliteal artery including open or endovascular revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major amputation</measure>
    <time_frame>1-3-5 years</time_frame>
    <description>Major amputation for patients with chronic limb-threatening ischemia</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>PAD</condition>
  <arm_group>
    <arm_group_label>paclitaxel coated balloon angioplasty</arm_group_label>
    <description>Procedures with paclitaxel coated balloon angioplasty of the superficial femoral-popliteal artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>plain balloon angioplasty</arm_group_label>
    <description>Procedures with plain balloon angioplasty of the superficial femoral-popliteal artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel eluting stent</arm_group_label>
    <description>Procedures with paclitaxel eluting stenting of the superficial femoral-popliteal artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bare metal stenting</arm_group_label>
    <description>Procedures with bare metal self expanding stenting of the superficial femoral-popliteal artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pactlitaxel PAD device</intervention_name>
    <description>Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.</description>
    <arm_group_label>paclitaxel coated balloon angioplasty</arm_group_label>
    <arm_group_label>paclitaxel eluting stent</arm_group_label>
    <other_name>Medtronic INPact Admiral</other_name>
    <other_name>Bard Lutonix</other_name>
    <other_name>Cook Zilver PTX stent</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients, aged 65 or older, who underwent endovascular interventional treatment of the
        femoral or popliteal arteries for symptomatic PAD between 10/1/2012 and the latest
        available CMS dataset (12/31/2016) will be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 65 years old

          -  Date of index procedure is within 10/1/2012 to 12/31/2016

          -  Symptomatic disease ranging from intermittent claudication to chronic limb-threatening
             ischemia (including ischemic rest pain and/or tissue loss)

          -  Elective or urgent procedures

        Exclusion Criteria:

          -  Aneurysmal disease of the superficial femoral or popliteal artery

          -  Treatment for acute limb ischemia

          -  Treatment of common femoral artery or profunda femoral artery occlusive disease

          -  Emergency procedures

          -  PVI and concomitant femoral endarterectomy, suprainguinal or infrainguinal bypass
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Bertges, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SVS VQI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Goodney, MD</last_name>
    <role>Study Director</role>
    <affiliation>SVS VQI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Art Sedrakyan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Jorgensen</last_name>
    <role>Study Chair</role>
    <affiliation>SVS PSO</affiliation>
  </overall_official>
  <reference>
    <citation>Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018 Dec 18;7(24):e011245. doi: 10.1161/JAHA.118.011245.</citation>
    <PMID>30561254</PMID>
  </reference>
  <reference>
    <citation>Columbo JA, Kang R, Hoel AW, Kang J, Leinweber KA, Tauber KS, Hila R, Ramkumar N, Sedrakyan A, Goodney PP. A comparison of reintervention rates after endovascular aneurysm repair between the Vascular Quality Initiative registry, Medicare claims, and chart review. J Vasc Surg. 2019 Jan;69(1):74-79.e6. doi: 10.1016/j.jvs.2018.03.423. Epub 2018 Jun 15.</citation>
    <PMID>29914838</PMID>
  </reference>
  <reference>
    <citation>Schillinger M, Minar E. Past, present and future of femoropopliteal stenting. J Endovasc Ther. 2009 Feb;16 Suppl 1:I147-52. doi: 10.1583/1545-1550-16.16.I-147. Review.</citation>
    <PMID>19317587</PMID>
  </reference>
  <reference>
    <citation>Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, Koppensteiner R, Minar E, Schillinger M. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1090-5. doi: 10.1002/ccd.22128.</citation>
    <PMID>19859954</PMID>
  </reference>
  <reference>
    <citation>Chowdhury MM, McLain AD, Twine CP. Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev. 2014 Jun 24;(6):CD006767. doi: 10.1002/14651858.CD006767.pub3. Review.</citation>
    <PMID>24959692</PMID>
  </reference>
  <reference>
    <citation>Eliason JL, Wainess RM, Proctor MC, Dimick JB, Cowan JA Jr, Upchurch GR Jr, Stanley JC, Henke PK. A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann Surg. 2003 Sep;238(3):382-9; discussion 389-90.</citation>
    <PMID>14501504</PMID>
  </reference>
  <reference>
    <citation>Earnshaw JJ, Whitman B, Foy C. National Audit of Thrombolysis for Acute Leg Ischemia (NATALI): clinical factors associated with early outcome. J Vasc Surg. 2004 May;39(5):1018-25.</citation>
    <PMID>15111854</PMID>
  </reference>
  <reference>
    <citation>Howard DP, Banerjee A, Fairhead JF, Hands L, Silver LE, Rothwell PM; Oxford Vascular Study. Population-Based Study of Incidence, Risk Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events: Implications for Prevention. Circulation. 2015 Nov 10;132(19):1805-15. doi: 10.1161/CIRCULATIONAHA.115.016424. Epub 2015 Sep 8. Erratum in: Circulation. 2015 Nov 10;132(19):e234.</citation>
    <PMID>26350058</PMID>
  </reference>
  <reference>
    <citation>Baril DT, Ghosh K, Rosen AB. Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population. J Vasc Surg. 2014 Sep;60(3):669-77.e2. doi: 10.1016/j.jvs.2014.03.244. Epub 2014 Apr 24.</citation>
    <PMID>24768362</PMID>
  </reference>
  <reference>
    <citation>Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Mar 21;69(11):1465-1508. doi: 10.1016/j.jacc.2016.11.008. Epub 2016 Nov 13. Review. Erratum in: J Am Coll Cardiol. 2017 Mar 21;69(11):1520.</citation>
    <PMID>27851991</PMID>
  </reference>
  <reference>
    <citation>Oakes D, Feng C. Combining stratified and unstratified log-rank tests in paired survival data. Stat Med. 2010 Jul 20;29(16):1735-45. doi: 10.1002/sim.3921.</citation>
    <PMID>20572124</PMID>
  </reference>
  <reference>
    <citation>M Grambsch and TM Therneau, Proportional Hazards Tests and Diagnostics Based on Weighted Residuals, Biometrika 1994, 81(3): 515-526, https://doi.org/10.1093/biomet/81.3.515</citation>
  </reference>
  <reference>
    <citation>Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013 Dec 7;13:152. doi: 10.1186/1471-2288-13-152.</citation>
    <PMID>24314264</PMID>
  </reference>
  <reference>
    <citation>Parzen M, Lipsitz SR. A global goodness-of-fit statistic for Cox regression models. Biometrics. 1999 Jun;55(2):580-4.</citation>
    <PMID>11318217</PMID>
  </reference>
  <reference>
    <citation>Heinze G, Wallisch C, Dunkler D. Variable selection - A review and recommendations for the practicing statistician. Biom J. 2018 May;60(3):431-449. doi: 10.1002/bimj.201700067. Epub 2018 Jan 2. Review.</citation>
    <PMID>29292533</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Bertges, MD</investigator_full_name>
    <investigator_title>Associate Professor of Surgery and Medicine</investigator_title>
  </responsible_party>
  <keyword>paclitaxel</keyword>
  <keyword>drug coated balloon</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>perihpheral vascular intervention</keyword>
  <keyword>registry</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT04204564/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

